RESUMEN
Gene therapy is one of the most advanced therapies in current medicine. In particular, interference RNA-based therapy by small interfering RNA (siRNA) has gained attention in recent years as it is a highly versatile, selective and specific therapy. In dermatological conditions, topical delivery of siRNA offers numerous therapeutic advantages, mainly by inhibiting the expression of target transcripts directly in the skin. However, crossing the stratum corneum and overcoming intracellular barriers is an inherent challenge. Substantial efforts by scientists have moved towards the use of multimodal and multifunctional nanoparticles to overcome these barriers and achieve greater bioavailability in their site of action, the cytoplasm. In this review the most innovative strategies based on nanoparticle and physical methods are presented, as well as the design principles and the main factors that contribute to the performance of these systems. This review also highlights the synergistic contributions of medicine, nanotechnology, and molecular biology to advancing translational research into siRNA-based therapeutics for skin diseases.
Asunto(s)
Nanopartículas , Enfermedades de la Piel , Humanos , ARN Interferente Pequeño , Interferencia de ARN , Terapia Genética/métodos , Preparaciones Farmacéuticas , Enfermedades de la Piel/tratamiento farmacológico , NanotecnologíaRESUMEN
Small interfering RNA (siRNA) molecules have limited transfection efficiency and stability, necessitating the use of delivery systems to be effective in gene knockdown therapies. In this regard, lipid-polymeric nanocarriers have emerged as a promising class of nanoparticles for siRNA delivery, particularly for topical applications. We proposed the use of solid lipid-polymer hybrid nanoparticles (SLPHNs) as topical delivery systems for siRNA. This approach was evaluated by assessing the ability of SLPHNs-siRNA complexes to internalize siRNA molecules and both to penetrate skin layers in vitro and induce gene knocking down in a skin cell line. The SLPHNs were formed by a specific composition of solid lipids, a surfactant polymer as a dispersive agent, and a cationic polymer as a complexing agent for siRNA. The optimized nanocarriers exhibited a spherical shape with a smooth surface. The average diameter of the nanoparticles was found to be 200 nm, and the zeta potential was measured to be +20 mV. Furthermore, these nanocarriers demonstrated excellent stability when stored at 4 °C over a period of 90 days. In vitro and in vivo permeation studies showed that SLPHNs increased the cutaneous penetration of fluorescent-labeled siRNA, which reached deeper skin layers. Efficacy studies were conducted on keratinocytes and fibroblasts, showing that SLPHNs maintained cell viability and high cellular uptake. Furthermore, SLPHNs complexed with siRNA against Firefly luciferase (siLuc) reduced luciferase expression, proving the efficacy of this nanocarrier in providing adequate intracellular release of siRNA for silencing specific genes. Based on these results, the developed carriers are promising siRNA delivery systems for skin disease therapy.
RESUMEN
INTRODUCTION: Lyotropic liquid crystals (LLCs) are organized mesophases with intermediate properties between liquids and solids. The LLC and its liquid crystalline nanoparticles (LCNPs) have attracted great interest from the scientific community in recent years as potential drug delivery systems due to the high internal ordering and symmetry with a wide interfacial area. AREAS COVERED: This article aims to gather information and to provide a description of the highly organized structures of LLCs. Updates on production methods and new insights for LCNPs optimization and physico-chemical and morphological caracterization techniques were discussed. We also discussed why these systems proved to be a platform for the design of nanocarrier drug delivery, with an emphasis on topical and transdermal applications. EXPERT OPINION: Drug delivery platforms are of particular importance to improve the biopharmaceutical aspects of therapies topically. Although several systems can be used, LLC or LCNPs appear to be favored due to their similarity to the lipid structure of the skin. The highly ordered structure and the possibility of chemical modifications make it possible to obtain better clinical responses. The results of several studies support the innovations in this field and predict that these systems can innovate the market of technologies for the treatment of cutaneous diseases and cosmetology.
Asunto(s)
Sistemas de Liberación de Medicamentos , Cristales Líquidos/química , Nanopartículas , Administración Cutánea , Animales , Humanos , Preparaciones Farmacéuticas/administración & dosificación , Piel/metabolismo , Enfermedades de la Piel/tratamiento farmacológicoRESUMEN
In this study, the development and the performance of a new targeted liquid crystalline nanodispersion (LCN) by the attachment of cell-penetrating peptides (CPP) onto their surfaces to improve skin delivery of lipoic acid (LA) were evaluated. For that, the synthesis and characterization of this new platform as well as its spatiotemporal analysis from in vitro and in vivo topical application were explored and extensively discussed in this paper. The TAT or D4 peptides were chosen as CPP due to specific target strategies by the charge grouping on the skin surface or target the overexpressed epidermal growth factor receptor (EGFR) of cell membrane of keratinocytes, respectively. Thus, the nanoparticle characterization results when taken together suggested that designed LCNs maintained their hexagonal phase structure, nanoscale particle size, and low polydispersity index even after drug, lipopolymers, and peptide additions, which are proved to be favorable for topical skin delivery. There were no statistical differences among the LCNs investigated, except for superficial charge of LCN conjugated with TAT which may have altered the LCN zeta potential due to cationic charge of TAT amino acid sequence compared with D4. The cumulative amounts of LA retained into the skin were determined to be even higher coming from the targeted LCNs. Moreover, the exogenous antioxidant application of the LA from the LCNs can prevent ROS damage, which was demonstrated by this study with the less myeloperoxidase (MPO) activity and decrease in cytokine levels (TNF-alpha and IL-1ß) generated by the oxidative stress modulation. Together, the data presented highlights the potential of these targeted LCNs, and overall, opens new frontiers for preclinical trials.
Asunto(s)
Antiinflamatorios , Péptidos de Penetración Celular , Nanopartículas , Piel/efectos de la radiación , Ácido Tióctico , Animales , Antiinflamatorios/administración & dosificación , Antiinflamatorios/farmacología , Masculino , Ratones , Absorción Cutánea , Ácido Tióctico/administración & dosificación , Ácido Tióctico/farmacología , Rayos UltravioletaRESUMEN
Triptolide (TPL) is a natural compound and active component of Tripterygium wilfordii Hook F., an Asian native woody vine widely used for over 200 years in Chinese medicine. Hot water, ethanol-ethyl acetate, and chloroform-methanol extracts are the first reported TPL preparations in the literature, and since then, several studies for application in inflammation processes and cancer are described due to the antitumor, anti-inflammatory, and immunosuppressive characteristics of the molecule. However, physicochemical properties such as poor solubility and bioavailability are the main concerns regarding the TPL safety and efficacy in clinical studies since trials have reported adverse side effects alongside the excellent TPL therapeutic effects. Here, we review the main TPL applications and issues related to the drug usage, and a comprehensive summary of diseases is provided. Special emphasis is given to drug delivery systems designed to overcome the TPL physicochemical characteristics such as poor drug solubility, and how to increase efficacy and obtain a safe drug profile. Graphical abstract.
Asunto(s)
Diterpenos , Medicamentos Herbarios Chinos , Fenantrenos , Diterpenos/farmacología , Medicamentos Herbarios Chinos/farmacología , Compuestos Epoxi , Fenantrenos/farmacología , TripterygiumRESUMEN
Skin cancer is a high burden disease with a high impact on global health. Conventional therapies have several drawbacks; thus, the development of effective therapies is required. In this context, nanotechnology approaches are an attractive strategy for cancer therapy because they enable the efficient delivery of drugs and other bioactive molecules to target tissues with low toxic effects. In this review, nanotechnological tools for skin cancer will be summarized and discussed. First, pathology and conventional therapies will be presented, followed by the challenges of skin cancer therapy. Then, the main features of developing efficient nanosystems will be discussed, and next, the most commonly used nanoparticles (NPs) described in the literature for skin cancer therapy will be presented. Subsequently, the use of NPs to deliver chemotherapeutics, immune and vaccine molecules and nucleic acids will be reviewed and discussed as will the combination of physical methods and NPs. Finally, multifunctional delivery systems to codeliver anticancer therapeutic agents containing or not surface functionalization will be summarized.
Asunto(s)
Antineoplásicos/uso terapéutico , Portadores de Fármacos/metabolismo , Nanopartículas/metabolismo , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Administración Cutánea , Antineoplásicos/administración & dosificación , Antineoplásicos/farmacología , Dacarbazina/farmacología , Dacarbazina/uso terapéutico , Portadores de Fármacos/administración & dosificación , Portadores de Fármacos/química , Resistencia a Antineoplásicos/fisiología , Fluorouracilo/farmacología , Fluorouracilo/uso terapéutico , Oro/química , Humanos , Melanoma/tratamiento farmacológico , Melanoma/patología , Nanopartículas del Metal/administración & dosificación , Nanopartículas del Metal/química , Nanopartículas/administración & dosificación , Nanopartículas/química , Nanotecnología , Tamaño de la Partícula , Absorción Cutánea/fisiología , Fenómenos Fisiológicos de la Piel , Propiedades de SuperficieRESUMEN
In this study, we developed a water-in-oil microemulsion containing vitamin A (retinol) and vitamin E (α-tocopherol), which serves as a multifunctional nanosystem that co-delivers antioxidants and displayed additive effect against acute skin inflammation. Microemulsion (ME) was prepared by mixing a surfactant blend (Tween 80 and propylene glycol, 5:1) with isopropyl myristate and water (ratio of 50:40:10, respectively). Vitamin A (0.05% w/w concentration) and/or vitamin E (0.1% w/w concentration) were incorporated into the surfactant mixture of ME by stirring with a magnetic stirrer for 30 min. This multifunctional ME displayed physical stability, with low cytotoxicity in 3T3 cell line, as well as cellular internalization into the cytosol. In vivo treatments using ME delivering α-tocopherol reduced dermal expression of TNF-α by 1.3-fold (pâ¯<â¯0.01), when compared to unloaded ME treatment group. When retinol was added into the ME containing α-tocopherol, it further reduced TNF-α expression by 2-fold (pâ¯<â¯0.001), suggesting the additive effect of vitamin E and vitamin A in the treatment against skin inflammation. In conclusion, we successfully developed the use of water-in-oil ME to pack both vitamin E and vitamin A, and demonstrated for the first time its anti-inflammatory potential when applied topically to TPA-induced inflamed skin.
Asunto(s)
Sistemas de Liberación de Medicamentos , Inflamación/tratamiento farmacológico , Inflamación/patología , Piel/patología , Vitamina A/administración & dosificación , Vitamina E/administración & dosificación , Enfermedad Aguda , Administración Tópica , Animales , Rastreo Diferencial de Calorimetría , Supervivencia Celular/efectos de los fármacos , Emulsiones , Células HaCaT , Humanos , Ratones , Ratones Pelados , Células 3T3 NIH , Piel/efectos de los fármacos , Porcinos , Vitamina A/farmacología , Vitamina A/uso terapéutico , Vitamina E/farmacología , Vitamina E/uso terapéuticoRESUMEN
Since psoriasis is an immuno-mediated skin disease, long-term therapies are necessary for its treatment. In clinical investigations, tacrolimus (TAC), a macrolide immunosuppressive inhibitor of calcineurin, arises as an alternative for the treatment of psoriasis, acting in some cytokines involved in the pathogenesis of the disease. Here, we aim to study the psoriasis treatment with TAC and siRNA for one of most cytokines expressed in psoriasis, the TNF-α. A multifunctional nanostructure lipid carrier (NLC) was developed to co-delivery TAC and siRNA. Results showed that the particle size and zeta potential were around 230 nm and + 10 mV, respectively. The release study demonstrated a controlled release of TAC, and the permeation and retention profile in the skin tissue show to be promising for topical application. The cell viability and uptake in murine fibroblast presented low toxicity associated to uptake of NLC in 4 h, and finally, the in vivo animal model demonstrates the efficiency of the NLC multifunctional, exhibiting a reduction of the cytokine TNF-α expression about 7-fold and presenting a synergic effect between the TAC and TNF-α siRNA. The developed system was successfully to treat in vivo psoriatic animal model induced by imiquimod and the synergic combination was reported here for the first time. Graphical abstract.
Asunto(s)
Imiquimod/efectos adversos , Psoriasis/tratamiento farmacológico , ARN Interferente Pequeño/administración & dosificación , Tacrolimus/administración & dosificación , Factor de Necrosis Tumoral alfa/genética , Administración Cutánea , Animales , Preparaciones de Acción Retardada , Modelos Animales de Enfermedad , Regulación hacia Abajo , Sinergismo Farmacológico , Femenino , Liposomas , Masculino , Ratones , Ratones Endogámicos BALB C , Células 3T3 NIH , Nanopartículas , Tamaño de la Partícula , Psoriasis/inducido químicamente , Psoriasis/genética , ARN Interferente Pequeño/farmacología , Tacrolimus/farmacología , Factor de Necrosis Tumoral alfa/antagonistas & inhibidoresAsunto(s)
Neoplasias/genética , Neoplasias/terapia , ARN Interferente Pequeño/genética , ARN Interferente Pequeño/uso terapéutico , Tratamiento con ARN de Interferencia , Enfermedades de la Piel/genética , Enfermedades de la Piel/terapia , Humanos , ARN Interferente Pequeño/administración & dosificaciónRESUMEN
BACKGROUND: Gene therapy is a new approach to discover and treat many diseases. It has attracted considerable attention from researchers in the last decades. The gene therapy through RNA interference has been considered one of the most recent and revolutionary approaches used in individualized therapy. In the last years, we have witnessed the rapid development in the field of the gene silencing and knockdown by topical siRNA. Its application in gene therapy has become an attractive alternative for drug development. METHODS: This article will address topical delivery of siRNA as a promising treatment for skin disorders. An update on the advances in siRNA-based nanocarriers as a powerful therapeutic strategy for several skin diseases will be discussed giving emphasis on in vitro evaluations. RESULTS: Through the in-depth review of the literature on the use of siRNAs for skin diseases we realize how widespread this use is. We have also realized that nanoparticles as non-viral vectors are increasingly being explored. Skin diseases where the use of siRNA has been explored most are skin cancer (melanoma and nonmelanoma), psoriasis, vitiligo, dermatitis and leprosy. But we also report here other diseases where the use of siRNA has been growing as acne, alopecia areata, cutaneous leishmaniasis, mycoses, herpes, epidermolysis bullosa and oculocutaneous albinism. Also highlighted, the first clinical trial of siRNA for cutaneous diseases, aimed at Pathyounychia Congenita. CONCLUSION: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin.
Asunto(s)
Sistemas de Liberación de Medicamentos , ARN Interferente Pequeño/administración & dosificación , ARN Interferente Pequeño/uso terapéutico , Tratamiento con ARN de Interferencia , Enfermedades de la Piel/genética , Enfermedades de la Piel/terapia , Animales , Humanos , ARN Interferente Pequeño/genéticaRESUMEN
Nanodispersions of liquid-crystalline phases (NLPs) composed of monoolein and oleic acid were chosen as nanocarriers to improve the topical retention of the photosensitizer protoporphyrin IX (PpIX) and thereby optimize photodynamic therapy (PDT) using this photosensitizer. The nanodispersions were characterized by polarized light microscopy, small-angle X-ray diffraction and dynamic light scattering. The stability and encapsulation efficiency (EE%) of the nanodispersions were also evaluated. In vitro and in vivo skin penetration studies were performed to determine the potential of the nanodispersions for cutaneous application. In addition, skin penetration and skin irritancy (in an animal model) after in vivo application were visualized by fluorescence light microscopy. The nanodispersion obtained was characterized as a monodisperse system (~150.0 nm) of hexagonal liquid-crystalline phase, which provided a high encapsulation efficiency of PpIX (~88%) that remained stable over 90 days of investigation. Skin penetration studies demonstrated that the nanodispersion enhanced PpIX skin uptake 11.8- and 3.3-fold (in vitro) and 23.6- and 20.8-fold (in vivo) compared to the PpIX skin uptake of control formulations, respectively. In addition, the hexagonal phase nanodispersion did not cause skin irritation after application for two consecutive days. Overall, the results show that the nanocarrier developed is suitable for use in topical PDT with PpIX.
Asunto(s)
Portadores de Fármacos/administración & dosificación , Glicéridos/administración & dosificación , Nanopartículas/administración & dosificación , Ácido Oléico/administración & dosificación , Fármacos Fotosensibilizantes/administración & dosificación , Protoporfirinas/administración & dosificación , Administración Tópica , Animales , Portadores de Fármacos/química , Portadores de Fármacos/farmacología , Femenino , Glicéridos/química , Glicéridos/farmacología , Técnicas In Vitro , Cristales Líquidos/química , Ratones Pelados , Nanopartículas/química , Ácido Oléico/química , Ácido Oléico/farmacología , Fotoquimioterapia , Fármacos Fotosensibilizantes/química , Fármacos Fotosensibilizantes/farmacología , Protoporfirinas/química , Protoporfirinas/farmacología , Piel/anatomía & histología , Piel/efectos de los fármacos , Piel/metabolismo , Suspensiones , PorcinosRESUMEN
Ultradeformable vesicles (UDV) have recently become a promising tool for the development of improved and innovative dermal and transdermal therapies. The aim of this work was to study three related UDV: transfersomes, ethosomes, and transethosomes for the incorporation of actives of distinct polarities, namely, vitamin E and caffeine, and to evaluate the effect of the carrier on skin permeation and penetration. These actives were incorporated in UDV formulations further characterized for vesicles imaging by transmission electron microscopy; mean vesicle size and polydispersity index by photon correlation spectroscopy; zeta potential by laser-Doppler anemometry; deformability by pressure-driven transport; and incorporation efficiency (IE) after actives quantification by high-performance liquid chromatography. Topical delivery studies were performed in order to compare UDV formulations regarding the release, skin permeation, and penetration profiles. All UDV formulations showed size values within the expected range, except transethosomes prepared by "transfersomal method", for which size was smaller than 100 nm in contrast to that obtained for vesicles prepared by "ethosomal method". Zeta potential was negative and higher for formulations containing sodium cholate. The IE was much higher for vitamin E- than caffeine-loaded UDV as expected. For flux measurements, the following order was obtained: transethosomes (TE) > ethosomes (E) ≥ transfersomes (T). This result was consistent with the release and skin penetration profiles for Vitamin E-loaded UDV. However, the releasing results were totally the opposite for caffeine-loaded UDV, which might be explained by the solubility and thermodynamic activity of this active in each formulation instead of the UDV deformability attending to the higher non-incorporated fraction of caffeine. Anyway, a high skin penetration and permeation for all caffeine-loaded UDV were obtained. Transethosomes were more deformable than ethosomes and transfersomes due to the presence of both ethanol and surfactant in their composition. All these UDV were suitable for a deeper skin penetration, especially transethosomes.
Asunto(s)
Cafeína/administración & dosificación , Portadores de Fármacos/química , Liposomas/química , Piel/efectos de los fármacos , Vitamina E/administración & dosificación , Administración Cutánea , Administración Tópica , Antioxidantes/administración & dosificación , Estimulantes del Sistema Nervioso Central/administración & dosificación , Química Farmacéutica , Cromatografía Líquida de Alta Presión , Sistemas de Liberación de Medicamentos , Humanos , Microscopía Electrónica de Transmisión , Absorción Cutánea , SolubilidadRESUMEN
Introdução: O uso de animais em pesquisa científica vem sendo ponto de discussão na última década, baseado na teoria dos 3Rs - Reduction, Refinement and Replacement. Objetivo: Avaliar o uso da pele de cobra brasileira (Crotalus durissus terrificus) como membrana biológica para ensaios in vitro de permeação cutânea, usando nicotina em adesivos transdérmicos como medicamento modelo. Há muitas similaridades nas taxas de permeação entre o estrato córneo humano e a pele de cobra, a qual sugere o uso da pele de cobra como um modelo de barreira nos ensaios de permeação através do estrato córneo. A pele de cobra pode vir a ser um substituto em potencial para o uso de animais de laboratórios, reduzindo o número de animais utilizados nas pesquisas, a dor e desconforto dos animais durante os experimentos. É importante procurar alternativas para substituição dos animais tanto em ensaios laboratoriais in vitro como nos ensaios in vivo. Material e Método: Experimento de laboratório. Ensaio in vitro de permeação cutânea utilizando pele de cobra pré-hidratada em água durante 12, 24 e 48 horas...
Introduction: Based on the theory of the 3Rs - Reduction, Refinement and Replacement, the use of animals in scientific research has been focused in the past decade. Objective: To assess the use of Brazilian snake (Crotalus durissus terrificus) skin as a biological membrane for in vitro skin permeation studies using nicotine transdermal patches as a drug model. There are many similarities in the permeation rates between the snake skin and the human stratum corneum, which suggest the use of this tissue as a barrier model to test drug permeation through the stratum corneum. The use of snake skin may become a potential replacement for the use of laboratory animals, reducing this way the number of animals used in research, as well as the pain and discomfort of animals during the experiments. It is important to seek alternatives in order to replace these animals both in vitro and in vivo laboratory assays. Materials and Methods: Laboratory Experiment During in vitro skin permeation studies using pre-treated with water hydration for 12, 24 and 48 hours snake skin, nicotine was used as a model drug, as well as a vertical diffusion cell as apparatus. The nicotine values permeated through snake skin were determined by High Performance Liquid Chromatography, being...
Introducción: El uso de animales en la investigación científica está siendo tema de debate en la última década, basado en la teoría de las 3Rs - Reducción, Refinamiento y Reemplazo. Objetivo: Evaluar el uso de la piel de serpiente brasileña (Crotalus durissus terrificus) como membrana biológica para las pruebas in vitro de la permeabilidad cutánea, el uso de la nicotina en parches transdérmicos como modelo de producto medicinal. Existen muchas similitudes entre los índices de permeabilidad en el estrato córneo y la serpiente humana, lo que sugiere el uso como modelo de barrera en las pruebas de la infiltración a través del estrato córneo. La serpiente puede ser un sustituto potencial para el uso de animales de laboratorio, reduciendo el número de animales utilizados en la investigación, el dolor y el sufrimiento de los animales durante los experimentos. Es importante buscar alternativas para animales de reemplazo tanto en pruebas de laboratorio ensayos in vivo e in vitro. Material y Método: Experimento de laboratorio - En ensayos de permeación in vitro utilizando piel de serpiente pre-tratados con hidratación en agua durante 12, 24 y 48 horas, la nicotina fue utilizado como um modelo de droga y célula de difusión vertical como lo aparato. Los valores de nicotina permeada por la piel de serpiente...
Asunto(s)
Animales , Animales de Laboratorio , Crotalus cascavella , Técnicas In Vitro/métodosRESUMEN
INTRODUCTION: Ultradeformable vesicles are highly promising tools to enhance the percutaneous transport of different drugs such as tretinoin across the skin barrier and also to increase the formulation stability at absorption site and reduce the drug induced irritation. METHODS: Topical delivery of tretinoin-loaded ultradeformable vesicles (tretinoin-UDV) was evaluated concerning different studies, such as: the release and permeation profiles (tape stripping); skin penetration (fluorescence analysis); induced electrical changes in skin barrier properties; cytotoxicity (Trypan Blue assay) and skin irritation in in vivo conditions (Draize test). The novel formulation performance was also compared to a commercial tretinoin formulation regarding in vivo studies. RESULTS: It was obtained a sustained and controlled drug release, as expected for UDV formulation. In addition, a dermal delivery was observed regarding the permeation study since it was not detected any drug amount in the receptor phase after 24h. Nile Red-UDV stained intensively mostly in the stratum corneum, corroborating the tape stripping results. Tretinoin-UDV decreased skin resistance, suggesting its ability to induce skin barrier disruption. Finally, the formulation vehicle (empty UDV) and tretinoin-UDV were not toxic under in vitro and in vivo conditions, at least, at 5×10(-3)mg/mL and 0.5mg/mL of tretinoin, respectively. CONCLUSION: Tretinoin-UDV is a promising delivery system for tretinoin dermal delivery without promoting skin irritation (unlike other commercial formulations), which is quite advantageous for therapeutic purpose.
Asunto(s)
Administración Tópica , Portadores de Fármacos , Sistemas de Liberación de Medicamentos , Piel/efectos de los fármacos , Tretinoina/administración & dosificación , Línea Celular , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Cromatografía Líquida de Alta Presión , Impedancia Eléctrica , Epidermis , Humanos , Queratinocitos/efectos de los fármacos , Luz , Liposomas/metabolismo , Nanotecnología , Oxazinas/química , Absorción Cutánea , Azul de Tripano/químicaRESUMEN
This experimental work aimed to develop a simple, fast, economic, and environmentally friendly process for the extraction of lycopene from tomato and incorporate this lycopene-rich extract into ultradeformable vesicular nanocarriers suitable for topical application. Lycopene extraction was conducted without a cosolvent for 30 min. The extracts were analyzed and incorporated in transfersomes and ethosomes. These formulations were characterized, and the cellular uptake was observed by confocal microscopy. Dermal delivery of lycopene formulations was tested under in vitro and in vivo conditions. Lycopene extraction proved to be quite safe and selective. The vesicular formulation was taken up by the cells, being more concentrated around the nucleus. Epicutaneous application of lycopene formulations decreased the level of anthralin-induced ear swelling by 97 and 87%, in a manner nonstatistically different from the positive control. These results support the idea that the lycopene-rich extract may be a good alternative to the expensive commercial lycopene for incorporation into advanced topical delivery systems.